INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Ottawa Hospital
Ottawa, CanadáPublicaciones en colaboración con investigadores/as de Ottawa Hospital (17)
2023
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
Future Oncology, Vol. 19, Núm. 5, pp. 345-353
-
The SUPER reporting guideline suggested for reporting of surgical technique: explanation and elaboration
Gland Surgery, Vol. 12, Núm. 6, pp. 749-766
2022
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260
2021
-
Developing the surgical technique reporting checklist and standards: a study protocol
Gland Surgery, Vol. 10, Núm. 8, pp. 2591-2599
-
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial
Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1413-1421
-
Evidence on reporting guidelines for surgical technique in clinical disciplines: a scoping review protocol
Gland Surgery, Vol. 10, Núm. 7, pp. 2325-2333
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
2019
2018
-
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Leukemia, Vol. 32, Núm. 8, pp. 1799-1803
-
Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia
New England Journal of Medicine, Vol. 378, Núm. 25, pp. 2399-2410
2017
-
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832
2016
-
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815
-
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study
The Lancet, Vol. 387, Núm. 10020, pp. 770-778
2013
-
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation
Journal of Clinical Oncology, Vol. 31, Núm. 13, pp. 1624-1630